menu
    • menu

    Company profile for CellVax Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At CellVax Therapeutics, we are actively engaged in the advancement of our exclusive cell-based cancer immunotherapy. Our primary product, FK-PC101, is designed to address the needs of prostate cancer patients at an elevated risk of recurrence following prostatectomy. This innovative therapy relies on our proprietary technology, which involves utilizing the patient's cancer cells to generate specialized Tumor Presenting Cells ...
    At CellVax Therapeutics, we are actively engaged in the advancement of our exclusive cell-based cancer immunotherapy. Our primary product, FK-PC101, is designed to address the needs of prostate cancer patients at an elevated risk of recurrence following prostatectomy. This innovative therapy relies on our proprietary technology, which involves utilizing the patient's cancer cells to generate specialized Tumor Presenting Cells (TPC). Through immunization with personalized TPC, patients can elicit a multi-neoantigen immune response targeting cancer cells.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CellVax TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1951 NW 7TH Av 3rd Floor
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cellvx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cellvax-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cellipont, CellVax Expand Partner for Manufacturing of FK-GI101
    Cellipont, CellVax Expand Partner for Manufacturing of FK-GI101

    29 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cellipont-bioservices-and-cellvax-therapeutics-expand-partnership-to-advance-cgmp-manufacturing-of-personalized-immunotherapy-fk-gi101-for-gi-cancers-302516193.html

    PR NEWSWIRE
    29 Jul 2025
    Share Share
    Theragent & CellVax Announce 1st Manufacturing Batch for FK-PC101 Trial
    Theragent & CellVax Announce 1st Manufacturing Batch for FK-PC101 Trial

    11 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/theragent-and-cellvax-therapeutics-announce-first-patient-dosed-in-phase-2-trial-of-fk-pc101-a-novel-personalized-cancer-immunotherapy-302300746.html

    PR NEWSWIRE
    11 Nov 2024
    Share Share
    CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101
    CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101

    29 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cellvax-therapeutics-announces-fda-clearance-of-ind-application-for-fk-pc101-a-novel-personalized-cancer-immunotherapy-302046986.html

    PR NEWSWIRE
    29 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search